International Research and Academic scholar society

Bacteriophage Therapy for Multidrug-Resistant Biofilm Infections: Engineering Phage Cocktails, Host Range Expansion, and Clinical Translation Frameworks


Sr No:
Page No: 18-37
Language: English
Authors: Tiku Kevin Tebeck*, Tayo Nguetsa Marcellin Girez, Yene Zang Bernard Severin, Mbone Toukaba Ines Pascale, Badie Moupain Idriss
Affiliation: University of Garoua, Faculty of medicine and Biomedical Science, Masters in Clinical Biology
Received: 2026-09-29
Accepted: 2026-11-03
Published Date: 2026-11-18
Abstract:
The accelerating crisis of antimicrobial resistance has rendered conventional antibiotics ineffective against a growing spectrum of multidrug-resistant (MDR) pathogens, particularly when these organisms establish biofilm communities on indwelling medical devices, chronic wounds, and prosthetic implants. Biofilm-associated infections represent a distinct therapeutic challenge: the three-dimensional extracellular polymeric substance (EPS) matrix not only physically excludes most antimicrobials but also harbors metabolically dormant persister cells that tolerate bactericidal concentrations of antibiotics. Bacteriophages, viruses evolved specifically to parasitize bacterial hosts offer a mechanistically orthogonal therapeutic modality that circumvents both chemical resistance mechanisms and biofilm architecture through enzymatic depolymerase activity and self-amplifying lytic cascades. This narrative review synthesizes current understanding across four intersecting domains that have heretofore been examined in isolation: the molecular basis of biofilm recalcitrance to antibiotics, phage-biofilm penetration dynamics, synthetic phage engineering strategies for host range expansion and biofilm degradation, and emerging clinical translation frameworks including compassionate-use programs and regulatory pathways. The synthesis reveals that while individual phage strains demonstrate remarkable biofilm-degrading capacity in vitro, clinical efficacy requires rationally designed phage cocktails that anticipate bacterial counterevolution, target multiple surface receptors, and encode complementary depolymerase enzymes. Critical gaps emerge at the interface of phage biology and clinical implementation: standardized manufacturing protocols remain absent, pharmacokinetic-pharmacodynamic relationships are poorly characterized for biofilm contexts, and validated biomarkers of therapeutic response do not exist. The regulatory landscape, while evolving through emergency investigational new drug (IND) pathways, lacks harmonized frameworks for adaptive phage therapy where strain selection must respond to real-time resistance emergence. Accumulating evidence from compassionate-use cases at specialized centers demonstrates clinical resolution of otherwise untreatable infections, yet the absence of randomized controlled trials limits broader adoption. The path forward necessitates coordinated efforts across synthetic biology, clinical microbiology, infectious disease medicine, and regulatory science. Immediate priorities include establishing phage banks with pre-characterized host ranges, developing point-of-care phage susceptibility testing, engineering broad-spectrum synthetic phages through tail fiber library construction, and implementing adaptive trial designs that accommodate personalized phage selection. The convergence of CRISPR-based antimicrobials, machine learning-guided phage discovery, and three-dimensional biofilm models positions phage therapy not as a historical curiosity but as a precision antimicrobial platform for the post-antibiotic era.
Keywords: bacteriophage therapy, multidrug resistance, biofilm infections, phage engineering, synthetic biology, antimicrobial resistance, regulatory pathways, personalized antimicrobials.

Journal: IRASS Journal of Applied Medical and Pharmaceutical Sciences
ISSN(Online): 3049-0901
Publisher: IRASS Publisher
Frequency: Monthly
Language: English

Bacteriophage Therapy for Multidrug-Resistant Biofilm Infections: Engineering Phage Cocktails, Host Range Expansion, and Clinical Translation Frameworks